Ibrumed 140mg Capsule

About

Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway. By irreversibly binding to BTK, ibrutinib blocks the proliferation and survival signals in malignant B-cells, leading to their apoptosis and inhibition of their migration and adhesion. This targeted therapy is particularly effective in B-cell malignancies where BTK signaling is dysregulated, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia (WM). Ibrutinib represents a significant advancement in the treatment of these conditions, offering an oral, less toxic alternative to traditional chemotherapy for many patients. Its mechanism of action specifically targets the underlying disease pathology, providing a more precise therapeutic approach.

Uses

• Treatment of chronic lymphocytic leukemia (CLL).
• Management of mantle cell lymphoma (MCL).
• Therapy for Waldenström's macroglobulinemia (WM).
• Treatment of marginal zone lymphoma (MZL).

Directions For Use

Take orally once daily with a glass of water, preferably at the same time each day. Do not open, break, or chew the capsule.

Benefits

• Targeted therapy with a specific mechanism of action.
• Oral administration, improving patient convenience.
• Effective in relapsed/refractory B-cell malignancies.
• Offers a chemotherapy-free treatment option.
• Can lead to durable responses and improved progression-free survival.
• Generally well-tolerated compared to conventional chemotherapy.

Side Effects

• Diarrhea
• Fatigue
• Nausea
• Muscle pain (myalgia)
• Rash
• Bruising
• Bleeding events (e.g., petechiae, epistaxis)
• Atrial fibrillation
• Hypertension
• Neutropenia
• Thrombocytopenia
• Upper respiratory tract infection

Safety Measures

• Alcohol - Limit or avoid alcohol consumption as it may increase the risk of certain side effects, such as gastrointestinal upset or bleeding, and can interact with drug metabolism.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception during treatment and for a period after.
• Breastfeeding - Contraindicated during breastfeeding as it is unknown if ibrutinib is excreted in human milk, but the potential for serious adverse reactions in breastfed infants exists.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments are typically required based on the severity of liver dysfunction, and liver function should be monitored.
• Kidney - Generally, no specific dose adjustment is needed for mild to moderate renal impairment, but caution is advised, and close monitoring of kidney function is recommended for severe impairment.
• Lung - Rare but serious pulmonary toxicities, including interstitial lung disease, have been reported. Patients should be monitored for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.